Business Description
Cosciens Biopharma Inc
NAICS : 325410
SIC : 3741
ISIN : CA1499071076
Total Employee Number:
28Description
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.48 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | -0.37 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 0.56 | |||||
Beneish M-Score | 1.55 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -32.6 | |||||
3-Year Book Growth Rate | -54.4 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 60.02 | |||||
9-Day RSI | 59.12 | |||||
14-Day RSI | 58.65 | |||||
3-1 Month Momentum % | -8.62 | |||||
6-1 Month Momentum % | 3.25 | |||||
12-1 Month Momentum % | -45.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.57 | |||||
Quick Ratio | 4.92 | |||||
Cash Ratio | 2.97 | |||||
Days Inventory | 127.77 | |||||
Days Sales Outstanding | 87.05 | |||||
Days Payable | 102.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -19.9 | |||||
Shareholder Yield % | -1.68 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 38.01 | |||||
Operating Margin % | -94.95 | |||||
Net Margin % | 51.13 | |||||
EBITDA Margin % | -70.16 | |||||
FCF Margin % | -112.7 | |||||
OCF Margin % | -111.52 | |||||
ROE % | 48.08 | |||||
ROA % | 16.22 | |||||
ROIC % | -54.13 | |||||
3-Year ROIIC % | 387.29 | |||||
ROC (Joel Greenblatt) % | -58.16 | |||||
ROCE % | -33 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 3.29 | |||||
Price-to-Owner-Earnings | 4.91 | |||||
PS Ratio | 1.08 | |||||
PB Ratio | 0.55 | |||||
Price-to-Tangible-Book | 0.54 | |||||
EV-to-EBIT | -0.14 | |||||
EV-to-EBITDA | -0.17 | |||||
EV-to-Revenue | 0.12 | |||||
EV-to-FCF | -0.43 | |||||
Price-to-GF-Value | 1.27 | |||||
Price-to-Median-PS-Value | 0.42 | |||||
| Price-to-Net-Current-Asset-Value | 1.41 | |||||
| Price-to-Net-Cash | 5.61 | |||||
Earnings Yield (Greenblatt) % | -729.01 | |||||
FCF Yield % | -141.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cosciens Biopharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 6.788 | ||
| EPS (TTM) (€) | 2.115 | ||
| Beta | -2.4709 | ||
| 3-Year Sharpe Ratio | 0.56 | ||
| 3-Year Sortino Ratio | 6.74 | ||
| Volatility % | 126.42 | ||
| 14-Day RSI | 58.65 | ||
| 14-Day ATR (€) | 0.832296 | ||
| 20-Day SMA (€) | 5.348274 | ||
| 12-1 Month Momentum % | -45.17 | ||
| 52-Week Range (€) | 1.493999 - 10.679999 | ||
| Shares Outstanding (Mil) | 1.06 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cosciens Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cosciens Biopharma Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| 0.333333:1 Stock Split | 2026-07-07 | 6.46 (+0.00%) |
Show
Entries
Cosciens Biopharma Inc Frequently Asked Questions
What is Cosciens Biopharma Inc(FRA:ET80)'s stock price today?
The current price of FRA:ET80 is €7.18. The 52 week high of FRA:ET80 is €10.68 and 52 week low is €1.49.
When is next earnings date of Cosciens Biopharma Inc(FRA:ET80)?
The next earnings date of Cosciens Biopharma Inc(FRA:ET80) is .
Does Cosciens Biopharma Inc(FRA:ET80) pay dividends? If so, how much?
Cosciens Biopharma Inc(FRA:ET80) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Cosciens Biopharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers